A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication A single center experience

Medicine (United States)

Volumn 95, Issue 24, 2016, Pages

  Abd Elsalam, Sherief ^a   Kobtan, Abdelrahman ^a   El Kalla, Ferial ^a   Elkhalawany, Walaa ^a   Nawasany, Sally El ^a   Saif, Sabry Abou ^a   Yousef, Mohamed ^a   Ali, Lobna Abo ^a   Soliman, Samah ^a   Mansour, Loai ^a   Habba, Eslam ^a   Soliman, Hanan ^a   Rizk, Fatma ^a   Shehata, Mona A H ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Helicobacter; Nitazoxanide; Rescue therapy

Indexed keywords

CLARITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; NITAZOXANIDE; OMEPRAZOLE; AMOXICILLIN; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ARTICLE; CONSTIPATION; DISEASE ERADICATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EGYPTIAN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; PRIORITY JOURNAL; SMOKING; UPPER GASTROINTESTINAL BLEEDING; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; ISOLATION AND PURIFICATION; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; OMEPRAZOLE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; THIAZOLES; TREATMENT OUTCOME;

EID: 84976351693     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003879     Document Type: Article

References (33)

1. Graham DY. Benefits from elimination of Helicobacter pylori infection include major reduction in the incidence of peptic ulcer disease, gastric cancer, and primary gastric lymphoma. Prev Med 1994;23: 712-6.
2. Peek MRJr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
3. Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
4. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;194:409-14.
5. Gisbert JP, González L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:1319-28.
6. Stenström B, Mendis A, Marshall B. Helicobacter pylori-the latest in diagnosis and treatment. Aust Fam Physician 2008;37:608.
7. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;263:343-57.
8. Graham DY, Shiotani A. Newer concepts regarding resistance in the treatment Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;56:321.
9. Hsu PI, Wu DC, Chen A, et al. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur J Clin Invest 2008;38:404-9.
10. Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.
11. Hojo M, Miwa H, Nagahara A, et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700.
12. Chey WD, Wong BCY. Practice Parameters Committee of the American College of Gastroenterology Management of Helicobacter pylori Infection. Am J Gastroenterol 2007;102:1808-25.
13. Dore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter 2003;8:307-9.
14. Zullo A, De Francesco V, Manes G, et al. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointestin Liver Dis 2010;192:131-4.
15. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-2.
16. Liou JM, Bair MJ, Chen CC, et al. Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of Helicobacter pylori: a randomized trial. Am J Gastroenterol 2016;1113:381-7.
17. Liang CM, Cheng JW, Kuo CM, et al. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomed J 2014;375:326-0.
18. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007;6713:1947-67.
19. Guttner Y, Windsor HM, Viiala CH, et al. Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob Agents Chemother 2003;4712:3780.
20. Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011;106:1970-5.
21. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-72.
22. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.
23. Arya SC. Nitazoxanide as a broad-spectrum antiparasitic agent. J Infect Dis 2002;185:1692.
24. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 1998;4211:2836-40.
25. Ramos-Soriano AG, Black J. Nitazoxanide use as part of an empiric multi-drug regimen in treating children with suspected Helicobacter pylori infection. Gastroenterol 2015;9:36-42.
26. Walker RC. Symposium on antimicrobial agents-part XIII: the fluoroquinolones. Mayo Clin Proc 1991;74:1030-7.
27. Di Caro S, Franceschi F, Mariana A, et al. Second line levofloxacin based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009;41:480-5.
28. Smilack JD. Symposium on anti microbial agents. part 10: the tetracyclines. Mayo Clin Proc 1999;74:727-9.
29. Duck MW, Sobel J, Pe-ruckler JM, et al. Anti microbial resistance incidence and risk factors among H pylori-infected persons, United States. Emerg Infec Dis 2004;10:1088-94.
30. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-57.
31. Romano M, Lovene MR, Russo MI, et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008;61:1112-5.
32. Carothers JJ, Bruce MG, Hennessy TW, et al. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007;44:e5-8.
33. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41:581-9.